NYSE:PFE - Pfizer Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$35.68 -0.21 (-0.59 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$35.68
Today's Range$35.5442 - $35.92
52-Week Range$31.67 - $39.43
Volume14.24 million shs
Average Volume23.21 million shs
Market Capitalization$214.12 billion
P/E Ratio13.46
Dividend Yield3.78%
Beta0.89

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:PFE
CUSIP71708110
Phone212-733-2323

Debt

Debt-to-Equity Ratio0.45
Current Ratio1.27
Quick Ratio0.98

Price-To-Earnings

Trailing P/E Ratio13.46
Forward P/E Ratio12.09
P/E Growth1.79

Sales & Book Value

Annual Sales$52.55 billion
Price / Sales4.04
Cash Flow$3.7205 per share
Price / Cash9.59
Book Value$11.85 per share
Price / Book3.01

Profitability

EPS (Most Recent Fiscal Year)$2.65
Net Income$21.31 billion
Net Margins41.29%
Return on Equity25.29%
Return on Assets9.78%

Miscellaneous

Employees90,200
Outstanding Shares5,952,870,000

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Thursday, April 26th. Stockholders of record on Friday, May 11th will be given a dividend of $0.34 per share on Friday, June 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.81%. The ex-dividend date is Thursday, May 10th. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer announced that its board has approved a stock repurchase program on Tuesday, December 19th 2017, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.03. The biopharmaceutical company had revenue of $12.91 billion for the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. Pfizer's revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.69 earnings per share. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

What price target have analysts set for PFE?

20 equities research analysts have issued 12-month price targets for Pfizer's stock. Their forecasts range from $36.00 to $43.50. On average, they expect Pfizer's share price to reach $40.2059 in the next year. View Analyst Ratings for Pfizer.

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 63,688,761 shares, an increase of 2.7% from the April 30th total of 65,448,096 shares. Based on an average daily volume of 24,821,410 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.1% of the shares of the company are sold short.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Chairman & CEO (Age 64)
  • Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
  • Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)
  • Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53)

Has Pfizer been receiving favorable news coverage?

News headlines about PFE stock have been trending positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pfizer earned a daily sentiment score of 0.36 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.59 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.72%), Northern Trust Corp (1.31%), Massachusetts Financial Services Co. MA (1.04%), Dimensional Fund Advisors LP (0.79%), Franklin Resources Inc. (0.75%) and Barrow Hanley Mewhinney & Strauss LLC (0.69%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Natixis, Swiss National Bank, FIL Ltd, Caisse DE Depot ET Placement DU Quebec, Levin Capital Strategies L.P., MUFG Securities EMEA plc and Legal & General Group Plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V., Neuberger Berman Group LLC, Mackay Shields LLC, Teacher Retirement System of Texas, LSV Asset Management and Summit Trail Advisors LLC. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $35.68.

How big of a company is Pfizer?

Pfizer has a market capitalization of $214.12 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (PFE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  969 (Vote Outperform)
Underperform Votes:  527 (Vote Underperform)
Total Votes:  1,496
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfizer (NYSE:PFE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Pfizer in the last 12 months. Their average twelve-month price target is $40.2059, suggesting that the stock has a possible upside of 12.68%. The high price target for PFE is $43.50 and the low price target for PFE is $36.00. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.352.372.422.56
Ratings Breakdown: 2 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $40.2059$39.2222$39.4444$38.5625
Price Target Upside: 12.68% upside7.99% upside10.58% upside8.66% upside

Pfizer (NYSE:PFE) Consensus Price Target History

Price Target History for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Credit Suisse GroupReiterated RatingNeutral$39.00LowView Rating Details
5/14/2018Jefferies GroupReiterated RatingNeutral$39.00LowView Rating Details
5/8/2018JPMorgan Chase & Co.Set Price TargetBuy$42.00LowView Rating Details
5/3/2018DZ BankReiterated RatingSellLowView Rating Details
5/2/2018MorningstarSet Price TargetBuy$43.50LowView Rating Details
5/2/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$43.00 ➝ $42.00LowView Rating Details
4/12/2018CitigroupReiterated RatingSellMediumView Rating Details
4/11/2018Berenberg BankReiterated RatingNeutral$37.00LowView Rating Details
4/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$41.00 ➝ $38.00MediumView Rating Details
1/31/2018Leerink SwannBoost Price TargetMarket Perform ➝ Market Perform$35.00 ➝ $38.00MediumView Rating Details
1/31/2018UBSSet Price TargetBuy$42.00MediumView Rating Details
1/31/2018Morgan StanleyBoost Price TargetOverweight ➝ Buy$41.00 ➝ $43.00MediumView Rating Details
1/31/2018Societe GeneraleSet Price TargetNeutral$40.00MediumView Rating Details
1/30/2018Goldman Sachs GroupSet Price TargetNeutral$36.00HighView Rating Details
1/30/2018Bank of AmericaSet Price TargetBuy$40.00MediumView Rating Details
1/30/2018Sanford C. BernsteinSet Price TargetBuy$43.00LowView Rating Details
1/29/2018SunTrust BanksReiterated RatingHold ➝ Hold$33.00 ➝ $40.00LowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralLowView Rating Details
12/6/2017Deutsche BankSet Price TargetBuy$38.00LowView Rating Details
8/14/2017CowenSet Price TargetBuy$43.00LowView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/2/2016ArgusDowngradeBuy ➝ HoldN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Pfizer (NYSE:PFE) Earnings History and Estimates Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Earnings Estimates

2018 EPS Consensus Estimate: $2.95
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.67$0.75$0.72
Q2 20182$0.70$0.77$0.74
Q3 20182$0.75$0.79$0.77
Q4 20182$0.64$0.82$0.73

Pfizer (NYSE PFE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018$0.74N/AView Earnings Details
5/1/2018Q1 2018$0.74$0.77$13.1381 billion$12.9060 billionViewN/AView Earnings Details
1/30/2018Q4 2017$0.5620$0.62$13.6746 billion$13.7030 billionViewListenView Earnings Details
10/31/2017Q3 2017$0.65$0.67$13.1749 billion$13.1680 billionViewN/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.0774 billion$12.8960 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.0890 billion$12.7790 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
11/2/2010Q3 2010$0.51$0.54ViewN/AView Earnings Details
8/3/2010Q2 2010$0.52$0.62ViewN/AView Earnings Details
5/4/2010Q1 2010$0.53$0.60ViewN/AView Earnings Details
2/3/2010Q4 2009$0.49$0.49ViewN/AView Earnings Details
10/20/2009Q3 2009$0.48$0.51ViewN/AView Earnings Details
7/22/2009Q2 2009$0.46$0.48ViewN/AView Earnings Details
4/28/2009Q1 2009$0.48$0.54ViewN/AView Earnings Details
1/26/2009Q4 2008$0.60$0.65ViewN/AView Earnings Details
10/21/2008Q3 2008$0.60$0.62ViewN/AView Earnings Details
7/23/2008Q2 2008$0.54$0.55ViewN/AView Earnings Details
4/17/2008Q1 2008$0.65$0.61ViewN/AView Earnings Details
1/23/2008Q4 2007$0.47$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pfizer (NYSE:PFE) Dividend Information

Pfizer pays an annual dividend of $1.36 per share, with a dividend yield of 3.81%. PFE's next quarterly dividend payment will be made on Friday, June 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 7.20% each year. Pfizer pays out 51.32% of its earnings out as a dividend.
Next Dividend:6/1/2018
Annual Dividend:$1.36
Dividend Yield:3.81%
Dividend Growth:7.20% (3 Year Average)
Payout Ratio(s):51.32% (Trailing 12 Months of Earnings)
46.10% (Based on This Year's Estimates)
44.59% (Based on Next Year's Estimates)
36.55% (Based on Cash Flow)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/26/2018quarterly$0.343.67%5/10/20185/11/20186/1/2018
12/18/2017quarterly$0.343.68%2/1/20182/2/20183/1/2018
9/27/2017quarterly$0.323.6%11/9/201711/10/201712/1/2017
6/22/2017quarterly$0.323.75%8/2/20178/4/20179/1/2017
4/28/2017quarterly$0.323.77%5/10/20175/12/20176/1/2017
12/12/2016quarterly$0.323.9%2/1/20172/3/20173/1/2017
9/23/2016quarterly$0.303.5%11/8/201611/11/201612/1/2016
6/23/2016quarterly$0.303.53%8/3/20168/5/20169/1/2016
4/28/2016quarterly$0.303.67%5/11/20165/13/20166/1/2016
12/14/2015quarterly$0.303.72%2/3/20162/5/20163/2/2016
9/25/2015quarterly$0.283.63%11/4/201511/6/201512/1/2015
6/25/2015quarterly$0.283.3%8/5/20158/7/20159/2/2015
4/23/2015quarterly$0.283.18%5/6/20155/8/20156/2/2015
12/15/2014quarterly$0.283.65%2/4/20152/6/20153/3/2015
10/23/2014quarterly$0.263.57%11/5/201411/7/201412/2/2014
6/26/2014quarterly$0.263.51%7/30/20148/1/20149/3/2014
4/25/2014quarterly$0.263.38%5/7/20145/9/20146/3/2014
12/16/2013quarterly$0.263.45%2/5/20142/7/20143/4/2014
10/24/2013quarterly$0.243.14%11/6/201311/8/201312/3/2013
6/27/2013quarterly$0.243.43%7/31/20138/2/20139/4/2013
4/25/2013quarterly$0.243.19%5/8/20135/10/20136/4/2013
12/17/2012quarterly$0.243.74%1/30/20132/1/20133/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 69.53%
Insider Trading History for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2018Ian C ReadCEOSell132,312$36.01$4,764,555.12View SEC Filing  
3/13/2018Douglas M LanklerInsiderSell50,000$36.89$1,844,500.00133,057View SEC Filing  
3/13/2018Rady A JohnsonEVPSell27,323$36.55$998,655.6570,332View SEC Filing  
3/9/2018Mikael DolstenInsiderSell69,699$36.59$2,550,286.41120,784View SEC Filing  
3/6/2018Charles H HillInsiderSell42,393$35.76$1,515,973.68View SEC Filing  
3/2/2018Mikael DolstenInsiderSell13,986$35.85$501,398.10120,884View SEC Filing  
2/27/2018Sally SusmanEVPSell33,368$37.03$1,235,617.04191,505View SEC Filing  
2/27/2018W Don CornwellDirectorSell1,758$36.79$64,676.821,000View SEC Filing  
2/26/2018Kirsten Lund-JurgensenInsiderSell9,510$37.19$353,676.9036,959View SEC Filing  
12/15/2017Alexander R MackenzieInsiderSell6,750$37.00$249,750.00103,458View SEC Filing  
12/15/2017Rady A JohnsonEVPSell8,000$37.07$296,560.0046,963View SEC Filing  
11/1/2017Alexander R MackenzieInsiderSell14,700$35.30$518,910.00117,432View SEC Filing  
10/2/2017Alexander R MackenzieEVPSell7,350$35.65$262,027.50117,432View SEC Filing  
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00145,649View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00124,774View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00132,124View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00337,389View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00580,318View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.8074,506View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00151,474View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.0054,963View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.0057,329View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.7064,719View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00112,087View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50149,199View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00472,994View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00271,663View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.0071,659View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00564,994View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00200,399View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.5088,922View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.001,446,738View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00195,951View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00124,920View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48438,107View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35372,994View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.002,489,364View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.0099,647View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15171,756View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62344,571View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15173,637View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20356,451View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70118,383View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pfizer (NYSE PFE) News Headlines

Source:
DateHeadline
$13.28 Billion in Sales Expected for Pfizer Inc. (PFE) This Quarter$13.28 Billion in Sales Expected for Pfizer Inc. (PFE) This Quarter
www.americanbankingnews.com - May 26 at 3:30 AM
Pfizers Tafamadis Gets Breakthrough Therapy DesignationPfizer's Tafamadis Gets Breakthrough Therapy Designation
finance.yahoo.com - May 25 at 10:19 AM
Pfizer To Pay $23.85 Mln To Resolve Kickback Claims: DoJPfizer To Pay $23.85 Mln To Resolve Kickback Claims: DoJ
www.nasdaq.com - May 25 at 10:19 AM
Pfizers Tafamidis a Breakthrough Therapy for rare heart disorderPfizer's Tafamidis a Breakthrough Therapy for rare heart disorder
seekingalpha.com - May 25 at 10:19 AM
Pfizer’s Products with Declining Revenues in Q1 2018Pfizer’s Products with Declining Revenues in Q1 2018
finance.yahoo.com - May 25 at 10:19 AM
Pfizer to pay $23.85 mln to resolve US kickbacks casePfizer to pay $23.85 mln to resolve US kickbacks case
www.reuters.com - May 24 at 3:41 PM
Pfizer executives are changing their tune on an approach for a promising new way to treat cancer, and it could be ...Pfizer executives are changing their tune on an approach for a promising new way to treat cancer, and it could be ...
www.businessinsider.com - May 24 at 3:41 PM
Pfizer to pay $23.9 million to resolve US kickbacks casePfizer to pay $23.9 million to resolve US kickbacks case
www.cnbc.com - May 24 at 3:41 PM
[$$] Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities[$$] Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities
finance.yahoo.com - May 24 at 3:41 PM
Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. SaysPfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says
finance.yahoo.com - May 24 at 3:41 PM
Pfizer to pay $23.85 million to settle kickback allegationsPfizer to pay $23.85 million to settle kickback allegations
finance.yahoo.com - May 24 at 3:41 PM
Pfizer agrees to pay nearly $24m to settle kickback claimsPfizer agrees to pay nearly $24m to settle kickback claims
www.ft.com - May 24 at 10:45 AM
Pfizer’s Growth Drivers in Q1 2018Pfizer’s Growth Drivers in Q1 2018
finance.yahoo.com - May 24 at 10:45 AM
3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More
investorplace.com - May 24 at 10:36 AM
$0.75 EPS Expected for Pfizer (PFE) This Quarter$0.75 EPS Expected for Pfizer (PFE) This Quarter
www.americanbankingnews.com - May 24 at 10:19 AM
EpiPen shortage heaps pressure on PfizerEpiPen shortage heaps pressure on Pfizer
seekingalpha.com - May 24 at 3:30 AM
Strata Oncology Secures $26 Million in Series B Funding, Led by Pfizer and MerckStrata Oncology Secures $26 Million in Series B Funding, Led by Pfizer and Merck
www.prnewswire.com - May 23 at 3:37 PM
More Than 200 Critical Drugs May Not Be There When You Need ThemMore Than 200 Critical Drugs May Not Be There When You Need Them
fortune.com - May 23 at 3:37 PM
Brainstorm Health: ADHD and Overdoses, Pfizer and the Drug Supply Chain, Geisinger DNA TestingBrainstorm Health: ADHD and Overdoses, Pfizer and the Drug Supply Chain, Geisinger DNA Testing
fortune.com - May 23 at 10:05 AM
Critical Condition: Inside Pfizers Drug Supply ProblemCritical Condition: Inside Pfizer's Drug Supply Problem
fortune.com - May 23 at 10:05 AM
Better Buy: AbbVie Inc. vs. Pfizer Inc.Better Buy: AbbVie Inc. vs. Pfizer Inc.
finance.yahoo.com - May 23 at 10:05 AM
FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin CardiomyopathyFDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy
finance.yahoo.com - May 23 at 10:05 AM
A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+
finance.yahoo.com - May 22 at 3:40 PM
Spark Therapeutics (ONCE) and Pfizer (PFE) Highlight Data from Ongoing Phase 1/2 Clinical Trial of Investigational ...Spark Therapeutics (ONCE) and Pfizer (PFE) Highlight Data from Ongoing Phase 1/2 Clinical Trial of Investigational ...
www.streetinsider.com - May 22 at 10:21 AM
Pfizer Begins Phase 1/2 Study To Evaluate Respiratory Syncytial Virus VaccinePfizer Begins Phase 1/2 Study To Evaluate Respiratory Syncytial Virus Vaccine
www.nasdaq.com - May 22 at 10:21 AM
BRIEF-Pfizer Begins Phase 1/2 Study To Evaluate Respiratory Syncytial Virus VaccineBRIEF-Pfizer Begins Phase 1/2 Study To Evaluate Respiratory Syncytial Virus Vaccine
www.reuters.com - May 22 at 10:21 AM
Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) VaccinePfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine
www.businesswire.com - May 22 at 10:21 AM
Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and ...Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and ...
globenewswire.com - May 22 at 10:21 AM
Pfizer (PFE) Begins a Phase 1/2 Study to Evaluate RSV VaccinePfizer (PFE) Begins a Phase 1/2 Study to Evaluate RSV Vaccine
www.streetinsider.com - May 22 at 10:21 AM
Gauging the Upside Potential of Vertex Pharmaceuticals StockGauging the Upside Potential of Vertex Pharmaceuticals Stock
finance.yahoo.com - May 22 at 10:21 AM
GlaxoSmithKline (GSK) with Pfizer (PFE) Reports ViiV Healthcare Granted EU Marketing Authorisation for Juluca ...GlaxoSmithKline (GSK) with Pfizer (PFE) Reports ViiV Healthcare Granted EU Marketing Authorisation for Juluca ...
www.streetinsider.com - May 21 at 10:30 AM
Credit Suisse Group Analysts Give Pfizer (PFE) a $39.00 Price TargetCredit Suisse Group Analysts Give Pfizer (PFE) a $39.00 Price Target
www.americanbankingnews.com - May 18 at 4:17 PM
Pfizers Epilepsy Drug Lyrica Succeeds in Pediatric StudyPfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
www.zacks.com - May 18 at 3:40 PM
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine DrugPharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
finance.yahoo.com - May 18 at 3:40 PM
Eli Lilly’s Valuation on May 17Eli Lilly’s Valuation on May 17
finance.yahoo.com - May 18 at 3:40 PM
Pfizers Lyrica successful in late-stage pediatric epilepsy studyPfizer's Lyrica successful in late-stage pediatric epilepsy study
seekingalpha.com - May 17 at 3:35 PM
Pfizer: Lyrica Oral Solution CV Phase 3 Trial Meets Primary EndpointPfizer: Lyrica Oral Solution CV Phase 3 Trial Meets Primary Endpoint
www.nasdaq.com - May 17 at 3:35 PM
Roches Alecensa beats Pfizers Xalkori in late-stage lung cancer studyRoche's Alecensa beats Pfizer's Xalkori in late-stage lung cancer study
seekingalpha.com - May 17 at 10:47 AM
BRIEF-Trial shows Pfizers Lyrica reduces seizures in children with epilepsyBRIEF-Trial shows Pfizer's Lyrica reduces seizures in children with epilepsy
www.reuters.com - May 17 at 10:47 AM
Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCOPfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO
www.businesswire.com - May 17 at 10:47 AM
Exelixis Is Expected to Report a Robust Revenue Rise in 2018Exelixis Is Expected to Report a Robust Revenue Rise in 2018
finance.yahoo.com - May 17 at 10:47 AM
Roche Tecentriq Combo Achieves Longer Overall Survival RateRoche Tecentriq Combo Achieves Longer Overall Survival Rate
finance.yahoo.com - May 17 at 10:47 AM
Sangamo Therapeutics Stock HistorySangamo Therapeutics Stock History
finance.yahoo.com - May 17 at 10:47 AM
Taking Stock of Gilead Sciences’ Key DevelopmentsTaking Stock of Gilead Sciences’ Key Developments
finance.yahoo.com - May 17 at 10:47 AM
Pfizer Gets FDA Nod for Amgen, J&Js Anemia Drug BiosimilarPfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
www.zacks.com - May 16 at 11:07 AM
Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug BiosimilarPfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
finance.yahoo.com - May 16 at 11:06 AM
BRIEF-PfizerS Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By US FDABRIEF-Pfizer'S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By US FDA
www.reuters.com - May 15 at 3:37 PM
Pfizers biosimilar of Amgen, J&Js anemia treatments gets FDA nodPfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod
finance.yahoo.com - May 15 at 3:37 PM
Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDAPfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA
finance.yahoo.com - May 15 at 3:37 PM
Azithromycin: A Generic Antibiotic That Continues To Provide Surprising Life-Saving BenefitsAzithromycin: A Generic Antibiotic That Continues To Provide Surprising Life-Saving Benefits
www.forbes.com - May 15 at 11:19 AM

SEC Filings

Pfizer (NYSE:PFE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pfizer (NYSE:PFE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pfizer (NYSE PFE) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.